Table 1.
Patient characteristics
| Basement characteristics | ALL (N = 310) | CB (N = 136) | BM (N = 119) | PBSC (N = 55) | P |
|---|---|---|---|---|---|
| Age, median (range), y | 51 (18-69) | 54 (18-69) | 47 (18-68) | 45 (18-69) | .062 |
| ≥51 | 160 (51.6) | 95 | 46 | 19 | <.001 |
| ≤51 | 150 (48.4) | 41 | 73 | 36 | |
| Sex, male, n (%) | 181 (58.4) | 73 (53.7) | 70 (58.8) | 38 (69.1) | .126 |
| HCT-CI, n or n (%) | |||||
| 0-2 | 196 (62.8) | 87 | 78 | 30 | .39 |
| ≥3 | 114 (36.8) | 49 | 41 | 25 | |
| Disease, n or n (%) | |||||
| AML | 168 (54.2) | 73 | 68 | 27 | .74 |
| ALL | 78 (25.2) | 37 | 28 | 13 | |
| MDS | 44 (14.2) | 19 | 15 | 10 | |
| CML | 9 (2.9) | 3 | 5 | 1 | |
| ML | 5 (1.6) | 3 | 1 | 1 | |
| Other | 6 (1.9) | 1 | 2 | 3 | |
| Refined-disease risk index, n or n (%) | |||||
| Low | 82 (26.4) | 37 | 32 | 13 | .92 |
| Intermediate | 92 (29.7) | 37 | 44 | 11 | |
| High | 70 (22.6) | 31 | 18 | 21 | |
| Very high | 66 (21.3) | 31 | 25 | 10 | |
| GVHD prophylaxis, n or n (%) | |||||
| Tacrolimus + sMTX | 230 (74.2) | 133 | 78 | 18 | <.001 |
| Cyclosporine + sMTX | 80 (25.8) | 2 | 40 | 37 | |
| Conditioning regimen, n or n (%) | |||||
| Myeloablative | 111 (35.8) | 34 | 58 | 19 | .036 |
| Reduced intensity | 199 (64.2) | 101 | 61 | 36 | |
| HLA antigen, n or n (%) | |||||
| 6/6 match | 157 (50.6) | 13 | 99 | 44 | .013 |
| 5/6 match | 57 (18.4) | 33 | 18 | 6 | |
| 4/6 match | 94 (30.0) | 88 | 2 | 4 | |
| 3/6 match or less | 3 (1.0) | 2 | 0 | 1 | |
| Donor relation, n or n (%) | |||||
| Related donor | 84 (27.1) | 0 | 40 | 44 | <.001 |
| Unrelated donor | 226 (72.9) | 136 | 79 | 11 | |
| Sex mismatch (donor to patient), n or n (%) | |||||
| Female to male | 75 (24.2) | 35 | 24 | 18 | .28 |
| Other | 235 (75.8) | 91 | 104 | 37 | |
| Diagnosis to transplant (NA = 1), d | |||||
| Median (range) | 189 (22-1373) | 108 (22-865) | 223 (99-1373) | 154 (38-987) | .04 |
| <180, n or n (%) | 147 (47.4) | 74 | 45 | 27 | .031 |
| ≥180, n or n (%) | 162 (52.2) | 62 | 73 | 28 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML; chronic myeloid leukemia; MDS, myelodysplastic syndrome; ML, malignant lymphoma; NA, data not available; sMTX, short-term methotrexate.